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ABSTRACT
Hyperactivation of the PI3K/AKT pathway is observed in most human cancer 
including lung carcinomas. Here we have investigated the role of miRNAs as 
downstream targets of activated PI3K/AKT signaling in Non Small Cell Lung Cancer 
(NSCLC). To this aim, miRNA profiling was performed in human lung epithelial cells 
(BEAS-2B) expressing active AKT1 (BEAS-AKT1-E17K), active PI3KCA (BEAS-PIK3CA-
E545K) or with silenced PTEN (BEAS-shPTEN).
Twenty-four differentially expressed miRNAs common to BEAS-AKT1-E17K, BEAS-
PIK3CA-E545K and BEAS-shPTEN cells were identified through this analysis, with 
miR-196a being the most consistently up-regulated miRNA. Interestingly, miR-196a 
was significantly overexpressed also in human NSCLC-derived cell lines (n=11) and 
primary lung cancer samples (n=28).
By manipulating the expression of miR-196a in BEAS-2B and NCI-H460 cells, 
we obtained compelling evidence that this miRNA acts downstream the PI3K/AKT 
pathway, mediating some of the proliferative, pro-migratory and tumorigenic activity 
that this pathway exerts in lung epithelial cells, possibly through the regulation of 
FoxO1, CDKN1B (hereafter p27) and HOXA9.
INTRODUCTION
Lung cancer is the most frequent cause of cancer-
related deaths worldwide that is divided in two main 
groups: small-cell lung cancer (SCLC, accounting 
approximately 20%) and non-small-cell lung cancer 
(NSCLC, approximately 80%) [1, 2]. Despite advances in 
early detection and standard treatment, NSCLC patients 
often have poor prognosis, with five-year survival rate less 
than 15% [3, 4].
Recent studies have shown that the 
phosphatidylinositol 3-kinase (PI3K) signaling cascade is 
frequently activated in human cancer [5–7]. PI3K signaling 
regulates multiple cellular processes that are critical for 
tumorigenesis that include cell proliferation, migration, 
apoptosis, glucose metabolism and angiogenesis [8, 9].
In NSCLC, aberrant activation of the PI3K/AKT 
pathway has been shown to contribute to both cancer 
initiation and progression [10–13]. Hyperactivation of 
AKT is detected in most NSCLC cell lines [14–16] and 
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in 30–75% NSCLCs [17–21], promoting resistance to 
chemo- and radiotherapy [15].
The end-point of the PI3K pathway is AKT, a 
small family of serine/threonine protein kinases. AKT is 
activated by recruitment to cell membrane via binding of 
its PH domain to 3′-phosphorylated phosphatidylinositols 
generated by PI3K and subsequent phosphorylation at T308 
and S473 [9, 14–27]. Conversely, the lipid phosphatase 
PTEN attenuates AKT activation by dephosphorylating the 
3′ position of phosphatidylinositols [28].
Once activated, AKT phosphorylates a number 
of downstream substrates that include Bad, Bim, 
procaspase-9, IκKalpha, the forkhead family of 
transcription factors FoxO1, FoxO3a, GSK-3β, the 
ubiquitin ligases MDM2 and SKP2, the CDK inhibitors 
p21 and p27 and others [29].
However, whereas the effects of AKT activation on 
mRNAs and proteins in the cell are known fairly well, so 
far the role of miRNAs as downstream targets of activated 
PI3K/AKT signaling is still poorly defined.
MiRNAs are small, conserved, noncoding RNAs 
of 18–25 nucleotides in length that act as negative 
regulators of many genes involved in cell development, 
differentiation, proliferation, survival and death [30]. 
For this reason, miRNAs are important players in the 
pathogenesis of cancer, acting either as oncogenes or 
tumor suppressor genes [31–33]. Expression of miRNAs 
is systematically altered in several cancers and the 
rearrangement of many genes encoding miRNAs has 
been associated to multiple cancers [34]. NSCLC samples 
frequently present alteration of the expression of miRNAs 
[35], and a plasmatic miRNA profile predicts the presence 
of an active disease [36]. Interestingly, miRNAs may act 
either as oncogenes or tumor suppressor genes and are 
involved in cancer initiation, dissemination and response 
to therapy [37–44].
To determine the role of miRNAs in lung cancer 
driven by aberrant PI3K/AKT signaling, we have 
examined changes in miRNA levels that are induced by 
alterations of this pathway through different mutations 
that are observed in human NSCLC [11], including a 
gain-of-function mutant of PIK3CA (E545K), a gain-of-
function mutant of AKT1 (E17K) and the loss of PTEN 
expression [12, 13, 45, 46]. Here we report that miR-196a 
is modulated by mutant PI3K, mutant AKT1 and by loss 
of PTEN, and represent a pivotal mediator of proliferation, 
migration/invasion and tumorigenicity elicited by aberrant 
activation of PI3K/AKT pathway.
RESULTS
Identification and validation of PI3K/AKT-
dependent miRNA expression signature
The aim of this study was to identify a miRNA 
signature of aberrant PI3K/AKT signaling in NSCLC 
cells. To this aim, we have genetically modified bronchial 
epithelial cells that recapitulate the most frequent 
alterations within the PI3K/AKT pathway. Immortalized, 
non-tumorigenic human bronchial epithelial cells 
(BEAS-2B) were engineered to express gain-of-function 
mutations of PIK3CA (PIK3CA-E545K), of AKT1 
(AKT1-E17K) or were silenced for PTEN (BEAS-AKT1-
E17K, BEAS-PIK3CA-E545K and BEAS-shPTEN, 
respectively) as described in previous work [47, 48]. 
However, to perform the experiments indicated below 
we infected BEAS-2B cells de novo so that both parental 
and derivative cells could be used at early passages. The 
presence of exogenous mutant PIK3CA, mutant AKT1 
or of endogenous wild-type PTEN proteins in transduced 
cells as well as the activation of PI3K/AKT signaling was 
determined by immunoblot and are shown in Figure 1.
MiRNAs targets of constitutive signaling of PI3K/
AKT in lung cancer cells were identified by miRNA 
profiling of BEAS-2B cells and derivatives. Expression 
values of miRNAs obtained were filtered for fold change 
>1.5 and subjected to t-test (p-value cut-off: 0.05) with 
Benjamini-Hochberg (B–H) FDR correction [49]. Analysis 
of the results allowed to identify 105 differentially 
expressed miRNAs (DEMs) in cells expressing mutant 
AKT1, comprising 42 up-regulated and 63 down-
regulated, 106 DEMs in cells expressing mutant PIK3CA, 
54 up-regulated and 52 down-regulated, and 91 DEMs in 
cells silenced for PTEN, 45 up-regulated and 46 down-
regulated (Figure 2A). The complete microarray data for 
all probe sets with the respective normalized values will 
be available at ArrayExpress (E-MTAB-4263) and are 
provided in additional files (Supplementary Tables S1-S3).
Based on the 3 lists of DEMs, we focused our 
attention on the miRNAs whose expression was 
influenced specifically by the oncogenic alteration of 
AKT1, PIK3CA or PTEN, and, alternatively, on those 
commonly deregulated by two or three of the above-
mentioned alterations. We thereby found that 41/1145 
DEMs analyzed (3.5%) were modulated by mutant 
AKT1 (15 up-regulated, 26 down-regulated), 42 DEMs 
analyzed (3.6%) were modulated by mutant PIK3CA (25 
up-regulated, 17 down-regulated) and 39 DEMs analyzed 
(3.4%) were modulated by PTEN loss (22 up-regulated, 17 
down-regulated; listed in Supplementary Tables S4-S6).
Once we have identified miRNAs regulated by 
activated AKT1 or PIK3CA, as well as those modulated by 
PTEN silencing, we proceeded to match the lists of DEMs 
in order to identify the miRNAs that, in lung cells, were 
common to the alterations of AKT1 and PIK3CA, AKT1 
and PTEN and/or PIK3CA and PTEN, respectively, or 
common to all 3 genetic alterations. These DEMs are more 
likely to be the most relevant mediators of aberrant PI3K/
AKT signaling in transformed bronchial epithelial cells. 
As shown in the Venn diagrams of Figure 2A, 14 DEMs 
(7 up-regulated, 5 down-regulated and 2 discordant) were 
common to BEAS-PIK3CA-E545K and BEAS-shPTEN, 
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26 (12 up-regulated, 12 down-regulated and 2 discordant) 
to BEAS-AKT1-E17K and BEAS-PIK3CA-E545K cells, 
14 (6 up-regulated, 7 down-regulated and 1 discordant) 
to BEAS-AKT1-E17K and BEAS-shPTEN cells and, 
finally, 24 (6 up-regulated, 13 down-regulated and 5 
discordant) to all three cell lines studied. This indicates 
that, altogether, aberrant PTEN/PI3K/AKT signaling 
regulated the expression of 200/1145 miRNAs (17.5%), 
though only 24 were common to all three alterations (2%).
Among the DEMs that were common to BEAS-
AKT1-E17K, BEAS-PIK3CA-E545K and BEAS-
shPTEN cells miR-203, miR-196a and miR-187 showed 
the highest fold changes. Conversely, among down-
regulated miRNAs common to all three aberrations, miR-
33a, miR-29c and miR-219-5p showed the highest fold 
changes. See Table 1 for a list of the most representative 
DEMs common to all three alterations with the 
corresponding fold-changes.
Figure 1: Expression of AKT1-E17K, PIK3CA-E545K, PTEN in BEAS-2B cells and derivatives. Immunoblot analysis of 
BEAS-2B cells and derivatives for the expression of the phosphorylation of AKT and for the expression of AKT1, PTEN, p110. ß-actin 
was used as loaded control.
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Categorization of DEMs regulated by PI3K/
AKT signaling in human lung epithelial cellsby 
Ingenuity Pathway Analysis
Subsequently, we investigated by Ingenuity Pathway 
Analysis (Ingenuity® Systems, http://www.ingenuity.
com, IPA) the functional significance of changes in the 
miRNA expression, and performed a categorization 
of these datasets into bio-functions and networks as 
indicated (Supplementary Figures S1-S2). The function 
“Reproductive System Disease” was the most frequent 
for the DEMs common to BEAS-AKT1-E17K, BEAS-
PIK3CA-E545K and BEAS-shPTEN, and was associated 
with 16 miRNAs, followed by “Cancer” (14 miRNAs), 
“Gastrointestinal Disease” (12 miRNAs), “Endocrine 
System Disorders” (10 miRNAs), and “Hepatic System 
Disease” (8 miRNAs), respectively.
We then analyzed the different categories associated 
with the bio-function “Cancer” and found different terms 
referring to lung cancer including “Lung squamous cell 
carcinoma” (2 molecules), “Small cell lung cancer” (1 
molecule), “Non small cell lung cancer” (2 molecules) 
(Supplementary Table S7). The DEMs identified within 
these functions were miR-16-1*/miR-16-5pand miR-203 
for the function “Lung squamous cell carcinoma”, miR-
19b for the function “Small cell lung cancer” and miR-
16-5p and miR-196a for the function “Non small cell lung 
cancer”, indicating that these DEMs as the most relevant 
Figure 2: MiRNA profiling of BEAS-2B cells and derivatives. A. Venn diagram of DEMs in BEAS-AKT1-E17K, BEAS-PIK3CA-
E545K and BEAS-shPTEN. B. Network analysis was performed to provide a graphical representation of miRNAs and genes having known 
biological relationships. Green icons indicate down-regulated miRNAs and genes and red icons indicates up-regulated miRNAs.
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for lung cancer. In particular, aberrant expression of miR-
196a has been frequently reported in various cancers 
including NSCLC [50–53] and it represents a major 
regulator of migration in NSCLC cells [54].
For further studies we chose miR-196a on the basis 
of the following considerations. MiR-196a was the DEM 
with the highest average fold change, being >2 in all three 
BEAS-AKT1-E17K, BEAS-PIK3CA-E545K and BEAS-
shPTEN cell lines. MiR-196a also turned out to be the only 
DEM present in relevant networks (Figure 2B, Network 2) 
by IPA analysis where it was the most highly up-regulated 
among the DEMs of Network 2 (Supplementary Figure S2).
Analysis of miR-196a expression in NSCLC-
derived cell lines and primary tumors
First, we confirmed expression of miR-196a in 
BEAS-2B cells and derivatives by using quantitative 
RT-PCR (Figure 3A). Subsequently, we analyzed the 
expression of miR-196a in NSCLC cell lines and primary 
tumors. Figure 3B shows the levels of miR-196a in 
11 cell lines derived from human NSCLCs (A549, 
BEN, NCI-H226, NCI-H292, NCI-H460, NCI-H522, 
NCI-H596, NCI-H727, NCI-H838, NCI-H1299, 
NCI-H1975). Primary human normal bronchial epithelial 
cells (NHBE) were used as control of normal lung and 
set arbitrarily as 1. Expression analysis of miR-196a by 
quantitative RT-PCR showed that the levels of miR-196a 
were significantly increased in all but two NSCLC-derived 
cell lines compared to NHBE used as control normal cells.
Furthermore, we observed also that miR-196a is 
overexpressed in primary NSCLC samples [n=28; 12 
squamous cell carcinomas (SCC), 8 carcinoids (CAR), 5 
adenocarcinomas (ADC), 2 large cell carcinomas (LCC) 
and 1 adeno-squamous carcinoma (ADS)]. As controls, 6 
matched normal samples were analyzed and set arbitrarily 
Table 1: The most significant DEMs modulated in BEAS-2B cells that are common to mutant AKT1, PIK3CA or 
PTEN loss with their relative fold change
Up-regulated miRNAs (Fold change)
miRNA ID
BEAS-AKT1-E17K
(fold change)
BEAS-PIK3CA-E545K
(fold change)
BEAS-shPTEN
(foldchange)
hsa-miR-196a 8.3 3.1 2.7
hsa-miR-203 6.5 1.9 7.4
hsa-miR-187 2.6 3.2 1.9
hsa-miR-628-5p 2.3 1.7 2.3
HS_243.1 2.3 1.7 3.6
HS_284.1 1.9 1.8 2.5
Down-regulated miRNAs (Fold change)
miRNA ID
BEAS-AKT1-E17K
(fold change)
BEAS-PIK3CA-E545K
(fold change)
BEAS-shPTEN
(foldchange)
hsa-miR-33a -16.1 -7.2 -8.8
hsa-miR-29c -7.4 -3.6 -4.4
hsa-miR-219-5p -5.2 -2 -3.6
hsa-miR-19b-1* -5.1 -2 -3.8
hsa-miR-16-1* -4.6 -2.9 -3.8
hsa-miR-424 -4.2 -2 -4.5
hsa-miR-24-1* -3.9 -2.3 -4.1
hsa-miR-542-3p -2.9 -2.2 -3.8
hsa-miR-29b -2.6 -2.1 -3.3
hsa-miR-301a -2.4 -1.8 -2
hsa-miR-107 -2 -1.7 -2.2
hsa-miR-101 -1.8 -1.9 -1.8
hsa-miR-188-5p -1.7 -1.6 -1.8
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as 1. As shown in Figure 3C, the average levels of miR-
196a were considerably higher in NSCLCs than in normal 
lung tissues (on average 14-fold).
Relationship between activity of the PI3K/AKT 
pathway and the expression of miR-196a
The overexpression of miR-196a in NSCLC is a 
common event, and it is not extremely novel per se. On 
the contrary, the novelty of this study resides in positioning 
miR-196a downstream the PI3K/AKT pathway. To further 
investigate the relationship between the PI3K/AKT pathway 
and miR-196a expression, first we correlated the levels 
of miR-196a with the activation status of the PI3K/AKT 
pathway in 7 NSCLC cell lines, of which the activation status 
of the PI3K/AKT pathway was known [12]. In this case, we 
found that 2 out of 3 pAKT negative cell lines presented low 
levels of miR-196a whereas 4/4 pAKT positive cell lines 
presented high levels of miR-196a. See Table 2.
However, this correlation was not confirmed 
when we used in silico data downloaded from the 
public repository of The Cancer Genome Atlas (TCGA) 
consortium (http://cancergenome.nih.gov/). In fact, we 
exploited the TCGA dataset to correlate the presence 
of activating mutations in genes within the PI3K/AKT 
pathway with the expression of miR-196a in multiple 
NSCLCs. Samples were divided into 2 different groups: 
i) tumors mutated for AKT1, PIK3CA and PTEN (n=32), 
and ii) the remaining wild type tumors (n=391). We 
found that in the group of mutant samples, 19/32 (59.3%) 
showed high levels of miR-196a whereas in the group 
of wild type samples, 192/391 (49.1%) showed high 
levels of miR-196a. Therefore, no statistically significant 
correlation was observed by Fisher’s Test.
Figure 3: Expression of miR-196a in lung cancer-derived cell lines and primary tumors. A. Relative mRNA expression of 
miR-196a by qRT-PCR in control BEAS-2B and derivatives. B. Expression of miR-196a in human NSCLC cell lines by qRT-PCR. Data are 
reported with respect to normal human bronchial epithelial cells (NHBE) whose value has been arbitrarily established as 1 and marked with 
a thick black line. Fold change values on y-axis are reported as log10. C. Expression of miR-196a in 28 human primary NSCLC samples by 
qRT-PCR. Normal human lung tissues (n=6) were used as controls to obtain an average expression value of miR-196a in normal lung that 
has been arbitrarily established as 1 and marked with a thick black line. Mean fold-change value (14) is shown as a blue line. Fold change 
values on y-axis are reported as log10.
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Subsequently, we added to the group under analysis 
tumors harbouring KRAS mutations, an alteration known 
to activate PI3K/AKT signaling. In this case mutant 
samples became 158. Of these 81 showed high levels of 
miR-196a expression (51.2%) whereas in the remaining 
265 non-mutant samples miR-196a was overexpressed in 
130 (49%). Again Fisher’s Test yielded non-significant 
values.
These contradictory results could be explained 
by the consideration that a correlation between mutated 
members of the PI3K/AKT pathway and miR-196a 
expression can be observed when simple systems such as 
cell lines are analyzed, but not when more complex and 
heterogeneous samples as tumors are considered.
A different approach to correlate the expression of 
miR-196a with the activity of the PI3K/AKT pathway 
was to determine the effects of suppressing the expression 
and/or activity of AKT isoforms in 2 different NSCLC 
cell lines (NCI-H460, A549) on miR-196a levels. To this 
aim we suppressed AKT1 and AKT2 expression in an 
established lung cancer cell line (NCI-H460) that harbours 
an activating mutation of PIK3CA (E545K) as reported 
[48]. In the work described in that manuscript, NCI-H460 
cells were transduced with lentivirus expressing three 
different shRNAs to AKT1 and AKT2.
Silencing of AKT1 in NCI-H460, as assessed by 
immunoblot [48], resulted in a marked reduction of miR-
196a levels as detected by quantitative RT-PCR (Figure 
4A), indicating that AKT kinases play a significant role 
in the expression of miR-196a in NSCLC cells. Similarly 
to AKT1 suppression, also the silencing of AKT2 in 
NCI-H460 cells produced a marked decrease in the levels of 
miR-196a as detected by quantitative RT-PCR (Figure 4A).
In addition, exposure of A549 NSCLC cells to 
MK2206, a pharmacological inhibitor of all AKT isoforms, 
markedly decreased AKT phosphorylation and significantly 
impaired miR-196a expression (Figure 4B). These results 
suggested that all the AKT isoforms expressed in the lung 
are able to increase miR-196a levels in NSCLC cells.
Finally, to investigate the presence of a mechanistic 
link between miR-196a and the PI3K/AKT pathway, 
we checked the promoter region of miR-196a for 
Transcriptional Factors’ binding sites, in particular those 
activated upon PI3K/AKT signaling. We reasoned that if 
the expression of miR-196a was under the transcriptional 
control of PI3K/AKT pathway, binding sites for 
Transcription Factors regulated by PI3K signaling in the 
promoter region of miR-196a should be identified.
Therefore, we performed a thorough analysis of 
statistically overrepresented MOTIF elements by Pscan 
(http://159.149.160.51/pscan/)[PSCAN], using RefSeq 
ID: NR_029582 as miR-196a identifier and Homo sapiens 
as source organism. The region analyzed was from −1000 
to +0 bp with regard to the annotated transcriptional start 
site of the miR-196a promoter, and employing Jaspar 2016 
as the database for the analysis. As a result, the output 
of the analysis returned a list of 50 Transcription Factors. 
See Supplementary Table S8. An element was considered 
to be significantly overrepresented if the P value was less 
than 0.05.
Among others, we found that the -1000/+0 promoter 
region of miR-196a contained the binding sites for 
FOXOq1, CREB3 and E2F, which are known to be activated 
by PI3K/AKT signaling [55–57] and thus are candidates to 
transcriptionally mediate PI3K/AKT-dependent regulation 
of miR-196a expression in NSCLC cells.
Overall these experiments indicate the existence 
of a tight loop between PI3K/AKT signaling and the 
expression of miR-196a in NSCLC cells that can be 
mediated by the binding of transcription factors regulated 
by PI3K/AKT to DNA sequences within the miR-196a 
promoter region.
MiR-196a stimulates anchorage-dependent and 
-independent proliferation in NSCLC cells
Given the importance of AKT signaling in the 
pro-migratory phenotype of NSCLC cells, [58, 59] we 
investigated the role of miR-196a on anchorage-dependent 
and independent growth, migration and tumorigenic 
potential of human NSCLC cells. To this aim, we made 
use of human bronchial epithelial cells (BEAS-2B) and 
the corresponding derivative that express activated AKT1-
E17K (BEAS-AKT1-E17K). See Supplementary Figure S3 
Table 2: Correlation between pAKT and miR-196a expression in NSCLC cell lines
Lung cancer cell lines p-AKT miR-196a FC
A549 + 5.98
BEN - 0.11
H226 - 0.46
H292 + 14.31
H460 + 14.43
H522 - 57.60
H596 + 2.46
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for expression of miR-196a in BEAS-2B cells transduced 
with control (EV) or miR-196a expressing lentiviruses 
(Supplementary Figure S3A) and BEAS-AKT1-E17K cells 
transduced with control (EV) or antimiR-196a expressing 
lentiviruses (Supplementary Figure S3B).
As an alternative approach, we suppressed 
miR-196a in the NSCLC cell line NCI-H460, which 
harbors a heterozygous activating mutation (E545K) 
in PIK3CA, resulting in activation of the PI3K/AKT 
pathway. See Supplementary Figure S3 for expression 
of miR-196a in NCI-H460 cells transduced with 
control (EV) or antimiR-196a expressing lentiviruses 
(Supplementary Figure S3C) and NCI-H460-shAKT1 
cells transduced with control (EV) or miR-196a 
expressing lentiviruses (Supplementary Figure S3D). 
Here we demonstrate that suppression of miR-196a 
expression by use of antimiR-196a in BEAS-2B and 
NCI-H460 cells reduced in vitro anchorage-dependent 
and -independent growth, in vitro migration and in vivo 
tumor growth of cells subcutaneously injected into 
immunodeficient mice (n = 4/group). Analysis of cell 
proliferation showed that antimiR-196a transduced into 
BEAS-2B cells reduced the proliferative capability of 
BEAS-E17K cells. Indeed, the growth curves in Figure 
5A indicated that after 96 hours the average number 
of BEAS-SCR-EV cells was 3.3±0.22x103, the average 
number of BEAS-E17K-EV cells was 8.7x103±1.8x102 
and the average number of BEAS-E17K-antimiR-196a 
cells was 7.7±0.19x103.
In NCI-H460 cells, antimiR-196a transduction 
significantly decreased cell proliferative rate with 
effects similar to, or even more pronounced of, those 
exerted by interference of AKT1 in NCI-H460 cells 
(NCI-H460-shAKT1). The growth curve in Figure 
5B showed that after 96 hours the average number 
of control NCI-H460 cells was 17.8±0.2x103, the 
average number of NCI-H460-shAKT1 cells was 
12.9±0.4x103 and the average number of NCI-H460-
SCR-antimiR-196a cells was 13.8±0.4x103. Conversely, 
overexpression of miR-196a in NCI-H460sh-AKT1 
cells caused a partial rescue of growth rate inhibited by 
AKT1 interference (Figure 5C).
In addition, miR-196a promoted anchorage-
independent growth in vitro, as BEAS-SCR-EV cells 
generated 216±36.8 colonies/well, BEAS-E17K-EV 
generated 519±46.5 colonies/well and BEAS-E17K-
antimiR-196a generated 393±24 colonies/well (Figure 5D; 
see Supplementary Figure S4 for representative images). 
Expression of miR-196a promoted anchorage-independent 
growth in vitro also in BEAS-2B cells, whereas its 
inhibition obtained by transducing a lentivirus expressing 
an antimiR-196a, partially counteracted the pro-mitogenic 
Figure 4: Suppression of AKT signaling on miR-196a expression in NSCLC cells. A. Relative mRNA expression of miR-196a 
by qRT-PCR in H460SCR, H460-shAKT1 and H460-shAKT2 cells. B. Relative mRNA expression of miR-196a by qRT-PCR in A549 cells 
treated with MK2206 and immunoblot for the expression of p-AKT and AKT1.
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effects induced by mutant AKT1 in BEAS-AKT1-E17K 
cells (Figure 5D).
In NCI-H460 cells inhibition of miR-196a by use of 
the specific antimiRNA markedly reduced the number of 
colonies/well (from 368±17.8 to 180±3.7). On the other 
hand, this miRNA increased the number of colonies/well 
when expressed into NCI-H460-shAKT1 cells (200±9.1 
vs. 134.5±28.9; Figure 5E; see Supplementary Figure S4 
for representative images).
These results indicate that miR-196a is able 
to promote anchorage-dependent and -independent 
proliferation of NSCLC cells.
MiR-196a stimulates migration and 
tumorigenicity in NSCLC cells
We then investigated whether miR-196a regulated 
migration in NSCLC cells and mediated, at least in part, 
the pro-migratory effects of activated AKT by Boyden 
chamber assays and wound assays. First, we found that 
expression of miR-196a increased migration of BEAS-2B 
cells of approximately 3-fold, whereas its inhibition by the 
antimiRNA in BEAS-AKT1-E17K cells counteracted the 
pro-migratory effects induced by mutant AKT1 (Figure 6A). 
On the other hand, inhibition of miR-196a markedly reduced 
Figure 5: MiR-196a regulates anchorage-dependent and –independent growth of NSCLC cells. A. MTT cell proliferation 
assay of BEAS-2B, BEAS-2B cells expressing antimiR-196a. Data are means ± SD calculated using triplicate samples in three separate 
experiments. p< 0.05. B. MTT cell proliferation assay of NCI-H460 cells expressing antimiR-196a. Data are means ± SD calculated using 
triplicate samples in three separate experiments. p< 0.05. C. MTT cell proliferation assay of NCI-H460-shAKT1 cells expressing miR-
196a. Data are means ± SD calculated using triplicate samples in three separate experiments. p< 0.05. D. Soft agar colony formation assay 
of BEAS-SCR-EV, BEAS-E17K-EV, BEAS-E17K-antimiR-196a. Bars represent the means of triplicate experiments ± SD. p<0.01. As 
controls we used: BEAS cells that were infected with a lentivirus expressing a MISSION pLKO.1-puro Non-Target shRNA Control Plasmid 
DNA that contains an shRNA insert that does not target any known gene from any species (BEAS-SCR cells); BEAS-2B and derivatives 
cells were infected with a control lentivirus carrying an empty pre-microRNA Expression Construct Lenti-miR (EV) (BEAS-SCR-EV and 
BEAS-E17K-EV, respectively). E. Soft agar colony formation assay of NCI-H460, NCI-H460-antimiR-196a, NCI-H460-shAKT1 and 
NCI-H460-shAKT1-miR-196a. Bars represent the means of triplicate experiments ± SD. p<0.01. As controls we used: NCI-H460 cells that 
were infected with a lentivirus expressing a MISSION pLKO.1-puro Non-Target shRNA Control Plasmid DNA that contains an shRNA 
insert that does not target any known gene from any species (NCI-H460 SCR cells); NCI-H460 and derivatives cells were infected with a 
control lentivirus carrying an empty pre-microRNA Expression Construct Lenti-miR (EV) (NCI-H460-SCR-EV and NCI-H460-shAKT1-
EV cells, respectively).
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NCI-H460 cell migration, assessed in Boyden chamber 
assays (140±18.9 vs 10.5±0.3 migrated cells; Figure 6B), 
whereas adoptive expression of miR-196a in NCI-H460-
shAKT1 cells rescued the impairment of cell migration 
induced by interference of AKT1 (158±26.8 vs 98±6.7).
These results were confirmed by wound assay of 
confluent monolayers of control NCI-H460, NCI-H460 
transduced with a lentivirus expressing antimiR-196a, 
NCI-H460-shAKT1, NCI-H460-shAKT1 transduced with 
miR-196a. As shown in Figure 6C, miR-196a suppression 
caused an almost 2-fold reduction in the capability of 
NCI-H460 cells to migrate at 48h after wounding. In 
agreement with these results, we found that miR-196a 
rescued the reduction of migrated cells induced by 
suppression of AKT1 in NCI-H460-shAKT1 cells. See 
Supplementary Figure S5 for representative images of 
wound closure.
Finally, suppression of miR-196a by use of antimiR-
196a markedly reduced in vivo tumor expansion of 
NSCLC cells injected into immunodeficient mice (n=4/
group) (Figure 6D), indicating that miR-196a plays a 
significant role in the malignant behavior of NSCLC cells.
Figure 6: MiR-196a regulates migration and tumorigenicity of NSCLC cells. A. Boyden chamber migration assay of control 
BEAS-SCR-EV, BEAS-SCR-miR-196a, BEAS-E17K-EV and BEAS-E17K-antimiR-196a cells. The graph represents the mean number 
(± SD) of migrated cells/field. Representative images of migrated BEAS-2B and derivative cells. Magnification 10X; p<0.001. B. Boyden 
chamber migration assay of control NCI-H460-SCR-EV, NCI-H460-shAKT1-EV, NCI-H460-SCR-antimiR-196a and NCI-H460-shAKT1-
miR-196a cells. The graph represents the mean number (± SD) of migrated cells/field. Representative images of migrated NCI-H460 
and derivative cells. Magnification 10X; p<0.001. C. Wound healing assay of NCI-H460-SCR-EV, NCI-H460-shAKT1-EV, NCI-H460-
shAKT1-miR-196a and NCI-H460-SCR-antimiR-196a cells. The graph represents the percentage of wound area reduction after 24h and 
48h from scratch. D. Tumor growth of NCI-H460-SCR-EV and NCI-H460-antimiR-196a cells injected into nude mice (n=4/group); data 
are shown as mean ± SD.
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Pro-tumorigenic activities exerted by miR-196a 
in NSCLC cells are partly mediated by FoxO1, 
p27 and HOXA9
To further dissect the biological contribution of 
miRNAs to aberrant PI3K/AKT signaling in NSCLC 
cells, we searched for miR-196a targets using TargetScan, 
microRNA.org and miRANDA. Target RNAs were 
selected on the basis of the number of databases that 
identified them. Using these criteria, and in consideration 
of previously published work [52, 60–62], we selected 
the transcription factor FoxO1 and cyclin-dependent 
kinase inhibitor p27 as effectors of miR-196a in NSCLC 
cells. This was strengthened also by our findings that this 
miR-196a stimulates proliferation in NSCLC cells (see 
above).
In Figure 7A are indicated the bioinformatic 
databases that support target prediction. Figure 7B shows 
the base-pairing of the seed sequence of miR-196a in the 
3’UTR of FoxO1 and p27 encoding genes. We confirmed 
that FoxO1 and p27 were bona fide targets of miR-196a 
in NSCLC cells, by performing immunoblot analyses in 
BEAS-2B cells expressing miR-196a and in NCI-H460 
cells in which the endogenous expression of miR-196a 
had been suppressed by use of anti-miR-196a (Figure 7C). 
Notably, BEAS-2B cells expressing AKT1-E17K showed 
similar modulation of p27 and FoxO1 proteins as 
BEAS-2B cells expressing miR-196a, and NCI-H460 
cells interfered for AKT1 showed similar modulation of 
CDKN1B and FoxO1 proteins as H460 cells-antimiR-
196a.
Finally, we searched for additional experimental 
evidence that FoxO1 and p27 mRNAs were targets of 
miR-196a by performing Luciferase assay. To this aim, 
HEK-293 cells were co-transfected with a pre-miR-196a 
oligonucleotide or a scrambled oligonucleotide (SCR), 
together with the 3'-UTR of FoxO1 (Luc-3’UTRFoxO1) 
or of p27 (Luc-3’UTR-CDKN1B) fused to Luciferase 
(Figure 7D, left and right, respectively). We found that 
the transfection of pre-miR-196a oligonucleotide, but not 
of the scrambled oligonucleotide, reduced the luciferase 
activity of approximately 20% for FoxO1 and 40% for 
p27.
To confirm that binding to seeds in the 3’UTR of 
FoxO1 and p27 was critical for miR-196a activity, we 
deleted the seed sequences of miR-196a in both target 
genes (3’UTR-FoxO1-DEL and 3’UTR-CDKN1B-
DEL) and performed Luciferase activity assay. These 
experiments demonstrated that the deletion of the seeds in 
both FoxO1 and p27 suppressed the activity of miR-196a, 
Figure 7: Role of predicted target genes of miR-196a in NSCLC cells. A. Target prediction of miR-196a. B. Base-pairing 
between the seed sequence of miR-196a and the 3’UTR of FoxO1 and p27. C. Immunoblot analysis of FoxO1 and p27 as indicated. D. Left 
panel, Luciferase assay of plasmids 3’UTR-FoxO1-WT and 3’UTR-FoxO1-DEL transfected into HEK-293 cells with pre-miR-196a or a 
no-targeting scrambled (SCR) oligonucleotides; right panel, Luciferase assay of plasmids 3’UTR-CDKN1B-WT and 3’UTR-CDKN1B-
DEL transfected into HEK-293 cells with pre-miR-196a oligonucleotide or a no-targeting scrambled oligonucleotide (SCR).
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thus suggesting that miR-196a reduces the expression of 
FoxO1 and of p27 by directly binding the seed sequences 
in their 3’-UTR (Figure 7D, left and right, respectively).
Subsequently, we investigated the relationship 
between miR-196a and its targets FoxO1 and p27.
As to FoxO1, we have silenced FoxO1 with siRNA. 
Analysis of cell proliferation by MTT and of cell migration 
through Boyden chamber assay, demonstrated that FoxO1 
expression has a moderate effect on cell proliferation of 
NSCLC cells and has no effect at all on migration (Figure 
8A–8B).
As to p27, we have previously demonstrated 
that its expression in lung epithelial cells inhibits 
completely growth and, on the contrary, the suppression 
of its expression by shRNA in BEAS-AKT1-E17K 
significantly increased cell proliferation and reduced 
cell migration [47]. These results indicate that both p27 
and FoxO1 regulate proliferation in BEAS-2B cells and 
that p27, but not FoxO1, is involved in the regulation of 
migration.
Another candidate for the regulation of migration 
in NSCLC cells is HOXA9 [63]. Data from the literature 
indicate that HOXA9, a negative regulator of migration 
in NSCLC cells, is a direct target for miR-196a [63, 64]. 
Thus, we investigated whether HOXA9 expression was 
regulated by miR-196a in NSCLC cells. Quantitative RT-
PCR analysis indicated that adoptive expression of miR-
196a in H460-shAKT1 cells induced a consistent down-
regulation of HOXA9 expression compared to the empty 
vector (Figure 8C).
The finding that adoptive expression of miR-196a 
in NSCLC cells induced a consistent down-regulation 
of HOXA9, suggests that miR-196a-mediated HOXA9 
down-regulation contributes to the pro-migratory effects 
exerted by miR-196a in NSCLC cells, though we can not 
formally exclude that HOXA9 regulation by miR-196 may 
take part also to the regulation of proliferative pathways.
DISCUSSION
Changes in the expression of miRNAs are 
associated with many human diseases including cancer 
[65–68], which has suggested a potential diagnostic 
or prognostic utilization of miRNAs in cancer [69]. 
Figure 8: A. MTT cell proliferation assay of BEAS-2B cells silenced for FoxO1 and immunoblot for FoxO1 expression. Data are means 
± SD calculated using triplicate samples in three separate experiments. p< 0.05. B. Boyden chamber migration assay of control BEAS-2B 
cells silenced for FoxO1. The graph represents the mean number (± SD) of migrated cells/field. Representative images of migrated BEAS-
2B cells silenced for FoxO1. Magnification 10X. C. Relative HOXA9 expression by qRT-PCR in NCI-H460-shAKT1-EV, NCI-H460-
shAKT1-miR-196a cells.
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However, the molecular mechanisms whereby miRNA 
expression is deregulated in cancer remain to be 
elucidated in several cases. Accordingly, although 
aberrant PI3K signaling is a frequent event in NSCLC 
cell lines [14–16] and primary tumors [17–21], there 
is no information so far about the role of miRNAs in 
mediating the effects exerted by oncogenic signaling 
elicited by activated PI3K pathway.
In this study, we have identified a group of 
miRNAs whose expression in lung cancer cells is 
increased/decreased when the PI3K/AKT pathway is 
oncogenically activated. In addition, we demonstrated 
that one such miRNA, miR-196a, mediates some of the 
transforming activities of activated PI3K/AKT pathway 
in NSCLC cells. These findings are noteworthy, as they 
shed light on the role exerted by miRNAs in aberrant 
PI3K signaling in NSCLC and, at the same time, provide 
experimental evidence that miR-196a can stimulate 
anchorage-dependent and -independent proliferation 
and migration in NSCLC cells downstream PI3K, thus 
ameliorating the comprehension of the pathogenesis of 
this neoplasia.
The data presented in this study demonstrate 
that aberrant PI3K signaling - induced by the adoptive 
expression of active mutant alleles of AKT1 or PI3KCA 
or by PTEN silencing - deregulates expression of 24 
miRNAs in human bronchial epithelial cells. Among 
these, the behavior of miR-16-1*/miR-16-5p and 
miR-203 was concordant with their putative anti-
oncogenic properties, whereas regulation of miR-196a 
was concordant with a supposed oncogenic effect. In 
particular, miR-196a, the DEM that showed the highest 
average fold change (>2) in all three derivatives of 
BEAS-cells (AKT1-E17K, BEAS-PIK3CA-E545K 
and BEAS-shPTEN), emerges as a critical player 
of PI3K signaling in lung cancer, regulating several 
oncogenic molecular networks. Expression of miR-196a 
expression in immortalized human bronchial epithelial 
cells (BEAS-2B) and/or its silencing in NSCLC cells 
harboring a PIK3CA mutation (NCI-H460), affected 
anchorage-dependent and -independent proliferation, 
migration and tumor growth in xenografts, further 
extending previous work performed in SPC-A1 and/or 
A549 cells in vitro [54].
MiR-196 is transcribed from three different genes 
denoted miR-196a-1, miR-196a-2 and miR-196b, with 
its expression strictly controlled in normal tissues [70]. 
Conversely, dysregulation of miR-196 expression is 
frequently observed in many cancer types including 
pancreatic, breast, colorectal, esophageal and lung 
carcinomas, as well as leukemias [8, 11–13, 70]. The 
results presented in this study, indicate that miR-196a 
is significantly overexpressed in human NSCLC-derived 
cell lines (n=9/11) and primary lung cancer samples 
(n=19/28), in particular, it is overexpressed in 9/12 
SCC, 4/8 CAR, 3/5 ADC, 2/2 LCC, 1/1 ADS. It should 
be noted that, while high miR-196a levels have been 
unequivocally associated with advanced clinical stage 
of disease and lymph-node metastasis, [71] the clinical 
significance of miR-196a up-regulation in NSCLC 
remains to be further confirmed, due to the small number 
of samples analyzed in this study.
The full spectrum of miR-196 actions in the 
different types of cancer cells is largely unknown. 
A complete understanding of the role that miR-196 
might play in cancer requires the identification of its 
targets. MiRNAs regulate gene expression by inhibiting 
synthesis of specific proteins via base-pairing of their 5’ 
nucleotides with the 3’UTR of target mRNA [70]. Recent 
work has shown that miR-196 targets FoxO1 in cervical 
cancer cells [62] and p27 in gastric cancer cells [52]. 
Based on these evidences, and on the predicted binding 
sites for miR-196a identified in this study, we observed 
that FoxO1 and p27 are direct targets of miR-196a in 
NSCLC cells.
Taken together, these results indicate that 
miR-196 plays a critical role in the pathogenesis of 
lung cancer, and that at least some of the oncogenic 
activities of miR-196a may depend on suppression of 
the expression of the transcription factor FoxO1 and/or 
the cyclin-dependent kinase inhibitor p27. Importantly, 
miR-196a has multiple effects on p27 levels - both 
direct and indirect. In fact, besides being controlled 
by miR-196, p27 expression is also regulated by FoxO 
transcription factors [72–74].
By suppressing FoxO1 and p27, miR-196a would 
thus stimulate cell cycle progression in NSCLC cells. 
As deregulation of CDK inhibitors such as p27 is 
commonly observed in tumor cells [75], overexpression 
of miR-196 may represent one mechanism whereby 
the activity of this important cell cycle inhibitor is 
impaired in cancer. Accordingly, we have previously 
demonstrated that suppression of p27 expression in lung 
epithelial cells completely inhibits growth and, on the 
contrary, the suppression of its expression by shRNA 
in BEAS-AKT1-E17K significantly increased cell 
proliferation and reduced cell migration [47]. On the 
other hand, silencing of FoxO1 had a moderate effect 
on cell proliferation and no effect at all on migration. 
Finally, the inhibition of HOXA9 by miR-196a may 
contribute to stimulate migration effects in NSCLC 
cells (Figure 9).
In conclusion, the data reported here provide strong 
support to the concept that expression of miR-196a is 
modulated by the most common alterations that contribute 
to the development of NSCLC, including activating 
mutations of PIK3CA (E545K) and AKT1 (E17K), and/or 
the loss of PTEN expression. MiR-196a could stimulate 
proliferation/migration by directly targeting FoxO1, p27 
and HOXA9 and thus plays an important role in mediating 
the effects exerted by aberrant activation of PI3K/AKT 
signaling.
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MATERIALS AND METHODS
Patients
Patient accrual was conducted according to internal 
Review Board of the INT Fondazione Pascale (Naples, 
Italy) (CEI 556/10 of 12/3/2010). The study was approved 
by the internal Review Board of the AOU Mater Domini/
University Magna Graecia (Catanzaro, Italy) in the 
meeting of 16/3/2011. Written informed consent was 
obtained from all participants to the study.
Archive material from 28 patients diagnosed of 
NSCLC was obtained from INT “Fondazione Pascale” 
(Naples, Italy).
Cell culture
A549, BEN, NCI-H226, NCI-H292, NCI-H460, 
NCI-H522, NCI-H596, NCI-H727, NCI-H838, 
NCI-H1299, NCI-H1975 human lung cancer cell lines 
were purchased from ATCC-LGC Promochem (South 
West London, UK) and maintained in RPMI 1640 (Lonza 
Walkersville Inc., MD) supplemented with 10% fetal 
bovine serum (Sigma-Aldrich, St.Luis, MO, USA) and 
100 units/ml penicillin-streptomycin (Lonza Walkersville 
Inc.). A549 cells were treated with MK2206 (Selleckchem, 
Huston, TX) at a concentration of 1μM for 3 hours.
NHBE, Normal Human Bronchial Epithelial cell 
line, was purchased from ATCC-LGC Promochem (South 
West London) and maintained in BEGM medium (Lonza).
BEAS-2B, immortalised human bronchial epithelial 
cell line was purchased from Chambrex (Milan, Italy) 
and grown according to the manufacturer’s protocol 
[76]. Transfection of siRNA was performed with 
MISSION®siRNA Transfection Reagent (S1452, Sigma 
Aldrich) by using 10nM of control (SIC007, Sigma 
Aldrich) and 10 nM of FoxO1 siRNA (PDSIRNA2D, 
Sigma Aldrich) according to the manufacturer’s protocol.
Generation of stably transfected cell lines
Human pre-microRNA Expression Construct Lenti-
miR-196a-1 (PMIRH196a1PA-1) and human miRZip-196a 
anti-miR-196a microRNA Construct (MZIP196a-PA-1) 
(System Biosciences, Mountain View, CA, USA) were 
used to generate lentiviral particles in HEK 293T packaging 
cells. As control, Scramble control hairpin in pCDH-
CMV-MCS-EF1-copGFP was used (PMIRH000PA-1, 
System Biosciences). HEK293T cells grown to 75% of 
confluency in culture (Corning Tewksbury, MA, USA) 
were transfected using the calcium phosphate precipitation 
method employing 13 μg of one of the two plasmids, 18 
μg of pCMV-deltaR8.91 and 12 μg of pCMV-VSVG [77]. 
The efficiency of transfection was evaluated by the analysis 
Figure 9: Model explaining the relationship among PI3K, AKT1, miR-196a, FoxO1, p27 and HOXA9.
Oncotarget15www.impactjournals.com/oncotarget
of transfected cells with a fluorescence microscope, due 
to the presence of the EGFP gene in the constructs for 
micro-RNA overexpression or knockdown. At 24 h after 
transfection, 4.5 ml of DMEM containing 10% FBS were 
added to the cultures. For lentiviruses producted to infect 
BEAS-2B cells, DMEM was complemented with 3% FBS. 
Supernatants harvested 48 h and 72 h post-transfection 
were filtered (0.22 μM, Millipore, Billerica, MA, USA) and 
directly used for infection cycles.
H460 (1x105 cells/well) and BEAS-2B cells 
(1.5x105 cells/well) were plated on six-well plates  
(Corning) 24 h before infection. A measure of 2ml of 
lentivirus supernatant containing 8 mg/ml polybrene 
(Sigma-Aldrich) were added to the cells. Spinoculation 
was performed at 2000 rpm, 30°C for 45 min. Two 
rounds of 12h infection were carried out. At the end of the 
infection procedure, supernatant containing lentiviruses 
was replaced with complete culture media. Fluorescent 
clones were picked up and amplified.
RNA extraction
Total RNA isolation from cells and clinical samples 
was performed with Trizol Reagent (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer’s protocol. 
RNA integrity was assessed by denaturing agarose gel 
electrophoresis.
miRNA Bead Chip microarray
RNA concentration was determined with a 
Nanodrop (NanoDrop, Wilmington, Delaware, USA) 
spectrophotometer. From each sample, technical replicates 
were produced and 600ng RNA were hybridized for 
18hrs to Human v2 MicroRNA Expression BeadChips 
(Illumina Inc., San Diego, CA, USA)as described earlier 
[78]. BeadChips were dried and scanned with an Illumina 
Bead Array Reader (Illumina Inc.). For data analysis, 
the intensity files were loaded into the Illumina Genome 
Studio V2011.1 software for quality control and miRNA 
expression analysis. First, the quantile normalization 
was performed using GeneSpring 13.1.1 (Agilent 
Technologies) to correct systematic errors. For differential 
expression analysis, technical replicates of each sample 
were grouped together to identify differentially expressed 
miRNAs having a fold change ≥ 1.5 and P < 0.05, as 
determined by Welch t test statistical analysis.
Gene characterization, enriched pathways and 
bibliographic networks discovery
The DEMs list was used to evaluate the functional 
behavior in terms of Biological Processes and Molecular 
Function, Development Function and Disease and Disorder 
terms. The degree of enrichment was statistically evaluated 
to determine whether an observed level of annotation for 
a group of genes is significant. In particular, for each 
term, a q-value was computed by the Hypergeometric test 
(p≤0.05) and corrected using False Discovery Rate (FDR). 
The terms with a q-value exceeding the significance 
threshold were then selected as representative. Pathway 
and network analysis were performed using Ingenuity 
Pathway Analysis (IPA, Ingenuity Systems). The dataset 
was mined for significant pathways with the IPA library 
of canonical pathways, and networks were generated by 
using IPA as graphical representation of the molecular 
relationships between genes and gene products. The 
significance of the association between the list of DEMs 
and the Canonical Pathway was measured using a Fisher’s 
exact test to calculate a p-value (p≤0.05). Fisher’s exact 
test results were also corrected for multiple testing using 
FDR. In networks miRNA, genes or gene products are 
represented as nodes, and the biological relationship 
between two nodes is represented as an edge (line). All 
edges are supported by at least one reference from the 
literature, from a textbook, or from canonical information 
stored in the IPA Knowledge Base. Human, mouse, and 
rat orthologs of a gene are stored as separate objects, 
but are represented as a single node in the network. The 
network building’s algorithm determines a statistical 
score for each network. This is done by comparing the 
number of focus genes that contribute to a given network 
relative to the total number of occurrences of those genes 
in all networks or pathways stored in the IPA Knowledge 
Base. The intensity of color in the networks indicates the 
degree of down-regulation (green) or up-regulation (red) 
of expression. Nodes are displayed using various shapes 
that represent the functional class of gene products.
Analysis of miR-196a promoter
Analysis of statistically over-represented MOTIF 
elements was conducted by Pscan (http://159.149.160.51/
pscan/) [PSCAN]. Significance of the results were 
assessed by calculatingp-values computed by Pscan with 
a z-test, which associates the probability of obtaining the 
same score on a random sequence set [PSCAN] with each 
profile. An element was considered to be significantly 
over-represented if the p-value was less than 0.05.
Quantitative real time RT-PCR (qRT-PCR)
Total RNA was reverse transcribed to cDNA using 
the Universal cDNA Synthesis kit II (Exiqon, Denmark). 
The q-PCR reaction was performed using the ExiLENT 
SYBR® Green Master Mix kit (Exiqon) utilized 
withLNA™ primers (Exiqon). The amount of each 
miRNA was normalized to the U6 RNA using the equation 
2-ΔCT, where ΔCT = (CTmiRNA- CTU6RNA).
Plasmids
For luciferase assays, the regions of 3’UTR of FoxO1 
and CDKN1B containing the miRNA binding sites were 
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cloned in pGL3 control vector (Promega, Milan, Italy) at 
XbaI restriction site, downstream luc gene. The 3’UTR 
regions of target genes were amplified from human blood 
cells genome by PCR reaction using the following primers:
primer forward FoxO1: CCCAATGTGTGCAGGT 
TATG; primer reverse FoxO1: AGGTCCAAGGCTGT 
TCAATG; primer forward CDKN1B: TTCATGGAATGG 
ACATCCTGT; primer reverse CDKN1B: CCTTCCCCAA 
AATTGCTTCT.
After cloning in DH5α bacteria strain, positive 
clones were identified by PCR on colonies using the same 
forward oligonucleotides described before and a reverse 
oligonucleotide that aligns on pGL3 control vector. 
Clones that were positive for PCR were screened also 
for digestion with XbaI. Only clones that were positive 
for both screenings were sequenced. Deletion of the seed 
sequence was performed by PCR.
These plasmids were used to transfect HEK293 cells 
with siPORT (Ambion Life Technologies, Paisley, UK) in 
the presence of mature microRNA-196a to evaluate the 
true bind of this miRNA to its own site on 3’UTR region 
of predicted target genes. Luciferase activity was assayed 
with a dual luciferase assay system (Promega, Milan, 
Italy) as described in the manufacturer instructions.
Western blot and antibodies
Whole cell protein extracts were prepared by 
homogenizing cells in NP-40 lysis buffer (10 mMTris–HCl 
(pH 7.5), 150 mMNaCl, 1% NP-40) containing protease 
inhibitors. Lysates were cleared by centrifugation and 
proteins were separated by SDS-PAGE. Proteins from 
gels were transferred to nitrocellulose membranes with 
TurboBlot System (Bio-rad Laboratories, Hercules, CA). 
The membranes were blocked with 5% nonfat dry milk in 
0.05% Tween-20 in TBS (TBST) for 1h at room temperature 
and then incubated with primary antibodies overnight at 4°C. 
After washing with TBST for three times (5 minutes each), 
the membranes were incubated for 1h at room temperature 
with 1:2500 diluted peroxidase-conjugated anti-rabbit IgG 
or peroxidase-conjugated anti-mouse IgG (GE Healthcare, 
Milan, Italy) as a secondary antibody. For detection, enhanced 
chemiluminescent reaction (GE Healthcare) was performed 
according to the manufacturer’s instructions.
Anti-phospho-AKT (Ser473) (#4058), anti-AKT1 
(#2938), anti-FoxO1 (#2880), anti-PI3K-p110 (#4255), 
were purchased from Cell Signaling Technology (Denver, 
MA, USA); anti-p27 antibody (C19) was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-β-
actin (#A2228) was purchased from Sigma-Aldrich; anti-
α-tubulin (Ab-2 DM1A, #MS-581-P0).
In vitro proliferation assay
Cell proliferation was assayed by MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide; 
Sigma-Aldrich] reduction. Cells were plated in 96-well flat-
bottomed microtiter plates (200 μl cell suspensions, 2×103/
well) and incubated with MTT substrate (5 mg/ml) for 2 
h. Every 24 hours, the culture medium was removed and 
anhydrous 2-propanol was added. The optical density was 
measured at 570 nm.
Wound healing assay
For wound healing assay cells were plated at equal 
density in six-well plates in duplicate and grown to 
confluence. Wounds were then generated with a sterile 
pipette, cells were rinsed twice with PBS, and fresh culture 
medium was added. Areas of wound were marked and 
photographed at 0 and 48h (Nikon Eclipse TE 2000-S). 
Wound area was measured with ImageJ software. Five 
different wound areas/well were analyzed.
Migration assay
Transwell migration assay was performed using six-
well Transwell polycarbonate filters (Sigma-Aldrich) with 
8-μm pore size. Cells (5x104) were seeded in the upper 
chamber of the Transwell insert and incubated for 48h at 
37°C in serum-free medium. Cells that did not migrate 
through the pores were manually removed with a cotton 
swab. Cells that migrated to the bottom of the membrane 
were fixed in cold methanol for 10 min and then stained 
with 0.01% crystal violet in 20% ethanol. Migrated cells 
were counted in 5 fields/well in triplicate experiments.
Soft agar assay
Cells (2.5×103 NCI-H460 cells; 5x103 BEAS-2B 
cells) were suspended in RPMI or BEBM, containing 
0.35% low-melting agarose (Type VII, Sigma-Aldrich) 
and seeded onto 0.5% low-melting agarose in six-well 
tissue culture plates. Colonies were scored after 3 weeks 
by staining with 0.1% crystal violet (Sigma-Aldrich) 
in methanol in 5 randomly selected fields/well, at 4X 
magnification. Quantification and SD were obtained from 
results of three independent experiments.
In vivo tumorigenic assay
NCI-H460 (2.5x106) were suspended in 50μl of 
PBS and 50μl of Matrigel Low Growth Factor (BD 
Biosciences, San Jose, CA, USA) and subcutaneously 
injected into the flank of 6-week-old nude mice (Charles 
River, West Germany) in quadruplicates. Every 7 days 
tumor size was measured with a caliper.
Statistical analysis
Data presented are the means ± SD of n independent 
assays or replicates as indicated in the text. Continuous 
variables were analyzed by Student’s t-test or ANOVA 
test. Significance was calculated by Prism 5 Software 
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(San Diego, CA, USA). Significance was set at p ≤ 0.05 
(*), p ≤ 0.01 (**), p ≤ 0.001 (***) and p ≤ 0.0001 (****), 
respectively.
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